A Single Ascending Dose of HRS-2162 in Healthy Subjects
ConditionReversal of Neuromuscular Blockade
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-45
SponsorFujian Shengdi Pharmaceutical Co., Ltd.
About this trial
The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
Eligibility criteria
Qualifiers
The subjects voluntarily signed the informed consent form.
Applicants must be between 18 and 45 years old at the time of signing the informed consent form, and both men and women are eligible .
ASA classification is Grade I (only Parts Two and three)
Male weight ≥50 kg, female weight ≥45 kg, body mass index between 19 and 28 kg/m ².
Disqualifiers
Those with a past or current clinical acute or chronic disease
Those with a history of hereditary bleeding or coagulation disorders or non-traumatic bleeding .
Those with a history of neuromuscular diseases or poliomyelitis
Those with a history of anesthesia complications.
Trial design
Treatments tested in this trial
- HRS-2162
- Placebo
Treatment groups
64 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov